Biomarkers of HIV-1 associated dementia: proteomic investigation of sera

BackgroundNew, more sensitive and specific biomarkers are needed to support other means of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/serum, including that there is no one proteomic platform that can offer complete identification of differences in proteomic profiles. Another set of problems is associated with heterogeneity of human samples in addition intrinsic variability associated with every step of proteomic investigation. Validation is the very last step of proteomic investigation and it is very often difficult to validate potential biomarker with desired sensitivity and specificity. Even though it may be possible to validate a differentially expressed protein, it may not necessarily prove to be a valid diagnostic biomarker.ResultsIn the current study we report results of proteomic analysis of sera from HIV-infected individuals with or without cognitive impairment. Application of SELDI-TOF analysis followed by weak cation exchange chromatography and 1-dimensional electrophoresis led to discovery of gelsolin and prealbumin as differentially expressed proteins which were not detected in this cohort of samples when previously investigated by 2-dimensional electrophoresis with Difference Gel Electrophoresis technology.ConclusionValidation using western-blot analysis led us to conclude that relative change of the levels of these proteins in one patient during a timeframe might be more informative, sensitive and specific than application of average level estimated based on an even larger cohort of patients.

[1]  Howard E. Gendelman,et al.  CSF proteomic fingerprints for HIV-associated cognitive impairment , 2007, Journal of Neuroimmunology.

[2]  G. Ellison.  PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) I. INVESTIGATION OF THE IMMUNOLOGIC STATUS OF A PATIENT WITH LYMPHOSARCOMA AND PML , 1969, Journal of neuropathology and experimental neurology.

[3]  S. Lipton,et al.  An overview of the clinical and biological features of the AIDS dementia complex. , 2005 .

[4]  R. Cutler,et al.  Novel markers of oxidative stress in actively progressive HIV dementia , 2004, Journal of Neuroimmunology.

[5]  W. Kiosses,et al.  Decreased neuronal autophagy in HIV dementia: A mechanism of indirect neurotoxicity , 2008, Autophagy.

[6]  Howard E Gendelman,et al.  Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. , 2007, Journal of proteome research.

[7]  H. Gendelman,et al.  Multidimensional protein fractionation using ProteomeLab PF 2D™ for profiling amyotrophic lateral sclerosis immunity: A preliminary report , 2008, Proteome Science.

[8]  C. Polman,et al.  Biological markers in CSF and blood for axonal degeneration in multiple sclerosis , 2005, The Lancet Neurology.

[9]  Frederick P Roth,et al.  Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[10]  N. Anderson,et al.  The Roles of Multiple Proteomic Platforms in a Pipeline for New Diagnostics , 2005, Molecular & Cellular Proteomics.

[11]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[12]  A. Venkatesan,et al.  Evolution of HIV dementia with HIV infection , 2008, International review of psychiatry.

[13]  S. Spector,et al.  Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children. , 1996, The Journal of infectious diseases.

[14]  K. Blennow,et al.  Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease , 2008, Neurobiology of Aging.

[15]  T. Veenstra,et al.  The Human Plasma Proteome , 2004, Molecular & Cellular Proteomics.

[16]  Frederick A. Schmitt,et al.  The HIV Dementia Scale: Predictive power in mild dementia and HAART , 2007, Journal of the Neurological Sciences.

[17]  D. Desiderio,et al.  Proteomics analysis of human cerebrospinal fluid. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  J. McArthur,et al.  Is the glass three-quarters full or one-quarter empty? , 2006, The Journal of infectious diseases.

[19]  M. Chamberlain,et al.  A Progressive Neurologic Disorder with Multiple CNS Lesions: A Neuroimaging Clinicopathologic Correlation , 2008, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[20]  James R. Anderson,et al.  Proteomic fingerprints distinguish microglia, bone marrow, and spleen macrophage populations , 2005, Glia.

[21]  Gilbert S. Omenn,et al.  Advancement of Biomarker Discovery and Validation through the HUPO Plasma Proteome Project , 2004, Disease markers.

[22]  M. Nissum,et al.  Analysis of human plasma proteins: a focus on sample collection and separation using free-flow electrophoresis , 2008, Expert review of proteomics.

[23]  P. Janmey,et al.  Gelsolin concentration in cerebrospinal fluid from patients with multiple sclerosis and other neurological disorders , 2008, European journal of neurology.

[24]  N Leigh Anderson,et al.  High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. , 2008, Clinical chemistry.

[25]  C P Das,et al.  Neurological complications of HIV infection. , 1998, Neurology India.

[26]  J. Becker,et al.  Neuropsychological performance in HIV‐1‐infected homosexual men , 1990, Neurology.

[27]  N. Sacktor,et al.  Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system , 2006, Current opinion in neurology.

[28]  H. Gendelman,et al.  Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis. , 2006, Current HIV research.

[29]  R. Harrington,et al.  Identification of Disease Markers in Human Cerebrospinal Fluid Using Lipidomic and Proteomic Methods , 2005, Disease markers.

[30]  Gunhild Waldemar,et al.  Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. , 2007, Archives of neurology.

[31]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[32]  Frank Vitzthum,et al.  Proteomics: from basic research to diagnostic application. A review of requirements & needs. , 2005, Journal of proteome research.

[33]  B. Ances,et al.  Dementia and Neurocognitive Disorders Due to HIV-1 Infection , 2007, Seminars in neurology.

[34]  D. Oxley,et al.  Disease Biomarkers in Cerebrospinal Fluid of Patients with First-Onset Psychosis , 2006, PLoS medicine.

[35]  James R. Anderson,et al.  Sera proteomic biomarker profiling in HIV‐1 infected subjects with cognitive impairment , 2008, Proteomics. Clinical applications.

[36]  Jeffrey R. Whiteaker,et al.  Head-to-head comparison of serum fractionation techniques. , 2007, Journal of proteome research.

[37]  M. Mattson,et al.  Associative and predictive biomarkers of dementia in HIV-1–infected patients , 2007, Neurology.

[38]  L. Honig,et al.  Laboratory biomarkers in Alzheimer’s disease , 2007, Current neurology and neuroscience reports.